Comparing two HER2-targeted drugs before surgery for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have not yet received any treatment for breast cancer.
- Your cancer is HER2-positive and either early-stage or locally advanced, confirmed by a biopsy.
- You are not pregnant and agree to use effective birth control if you could become pregnant.
- You must have adequate organ function, which will be checked with blood and urine tests.
- You can walk and take care of yourself (ECOG performance status of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs (Trastuzumab Rezetecan and Pertuzumab) given before surgery for HER2-positive breast cancer. The goal is to see if this approach shrinks tumors more effectively.
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial tests a new targeted drug called trastuzumab rezetecan (T-DXh) for patients with HER2-positive breast cancer who didn't have a complete response to standard chemotherapy and targeted drugs. The goal is to see if this new drug can help shrink remaining cancer.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.